This study was performed to validate whether MR contrast-enhancement in stromal tissue of the disease-free breast is related to the survival of patients with cancer in the other breast. A recent study in 398 patients with estrogen-receptor positive and human-epidermal-growth-factor-2 negative invasive breast cancer showed that more pronounced contralateral parenchymal enhancement (CPE) was associated with improved patient survival. In this study, we extracted CPE to re-test the finding in a comparable patient population from an independent cancer center. In 287 patients, CPE reproduces as a biomarker for long-term survival. This reproducible imaging finding has potential towards the personalization of care.